The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b

Journal of Clinical Investigation

Volumn 120, Issue 6, 2010, Pages 1971-1980

  Cao, Chunzhang ^a   Gao, Yamei ^a   Li, Yang ^a,c   Antalis, Toni M ^a   Castellino, Francis J ^b   Zhang, Li ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ACTIVATED PROTEIN C; BACTERIUM LIPOPOLYSACCHARIDE; CD11B ANTIGEN; CD18 ANTIGEN; ENDOTHELIAL PROTEIN C RECEPTOR; INTERLEUKIN 6; PROTEINASE ACTIVATED RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTOXEMIA; INFLAMMATION; LIPID RAFT; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; WILD TYPE;

1-CARBOXYGLUTAMIC ACID; ANIMALS; ENDOTOXEMIA; INTEGRINS; LIPOPOLYSACCHARIDES; LYSOPHOSPHOLIPIDS; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN C; SEPSIS; SPHINGOSINE;

EID: 77953202368     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI40380     Document Type: Article

References (45)

1. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov. 2005;4(10):854-865.
2. Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med. 2009;37(1 suppl):S30-S37.
3. Bernard GR, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709. (Pubitemid 32204987)
4. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269(42):26486-26491. (Pubitemid 24328474)
5. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257(14):7944-7947.
6. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-1882.
7. Tauseef M, et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res. 2008;103(10):1164-1172.
8. Cheng T, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9(3):338-342.
9. O'Brien LA, et al. Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation. Arterioscler Thromb Vasc Biol. 2007;27(12):2634-2641.
10. Kerschen EJ, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007;204(10):2439-2448.
11. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol. 1994;153(8):3664-3672.
12. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol. 2006;177(4):2115-2122.
13. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008;28(3):504-510.
14. Toltl LJ, Beaudin S, Liaw PC, Canadian Critical Care Translational Biology Group. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J Immunol. 2008;181(3):2165-2173.
15. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003;102(4):1499-1505.
16. Yang XV, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A. 2009;106(1):274-279.
17. Zheng X, et al. Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost. 2007;5(7):1394-1400.
18. Feistritzer C, Mosheimer BA, Sturn DH, Riewald M, Patsch JR, Wiedermann CJ. Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. J Immunol. 2006;176(2):1019-1025.
19. Li W, et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood. 2005;106(8):2716-2722.
20. Kurosawa S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol. 2000;165(8):4697-4703.
21. Li Z. The alphaMbeta2 integrin and its role in neutrophil function. Cell Res. 1999;9(3):171-178.
22. Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost. 2008;6(6):954-961.
23. Schuepbach RA, Feistritzer C, Brass LF, Riewald M. Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood. 2008;111(5):2667-2673.
24. Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res. 2008;102(8):950-958.
25. Rosenkranz A, et al. Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol. 1998;161(12):6463-6467.
26. Cao C, Lawrence DA, Strickland DK, Zhang L. A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood. 2005;106(9):3234-3241.
27. Coxon A, et al. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity. 1996;5(6):653-666.
28. Camerer E, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009;119(7):1871-1879.
29. Allende ML, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279(50):52487-52492.
30. Zemann B, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood. 2006;107(4):1454-1458.
31. Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol. 2005;77(2):129-140.
32. Elphick GF, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood. 2009;113(17):4078-4085.
33. Hamburger ZA, Brown MS, Isberg RR, Bjorkman PJ. Crystal structure of invasin: a bacterial integrin-binding protein. Science. 1999;286(5438):291-295.
34. Leong JM, Morrissey PE, Marra A, Isberg RR. An aspartate residue of the Yersinia pseudotuberculosis invasin protein that is critical for integrin binding. EMBO J. 1995;14(3):422-431.
35. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161-3172.
36. Esmon NL, DeBault LE, Esmon CT. Proteolytic formation and properties of gamma-carboxyglutamic acid-domainless protein C. J Biol Chem. 1983;258(9):5548-5553.
37. Mosnier LO, et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood. 2009;113(23):5970-5978.
38. Zhong Z, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119(11):3437-3449.
39. Berg DT, et al. Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A. 2003;100(8):4423-4428.
40. Gruber A, et al. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 1990;82(2):578-585.
41. Weiler H, Kerschen E. Modulation of sepsis outcome with variants of activated protein C. J Thromb Haemost. 2009;7(suppl 1):127-131.
42. Zhang L, Plow EF. Overlapping, but not identical, sites are involved in the recognition of C3bi, neutrophil inhibitory factor, and adhesive ligands by the alphaMbeta2 integrin. J Biol Chem. 1996;271(30):18211-18216.
43. Xiong YM, Chen J, Zhang L. Modulation of CD11b/CD18 adhesive activity by its extracellular, membrane-proximal regions. J Immunol. 2003;171(2):1042-1050.
44. Li Y, Zhang L. The fourth blade within the beta -propeller is involved specifically in C3bi recognition by integrin alpha Mbeta 2. J Biol Chem. 2003;278(36):34395-34402.
45. Cao C, et al. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J. 2006;25(9):1860-1870.